Phase 1 Trial of XmAb541 in Advanced Solid Tumors
Phase 1
212
about 4.7 years
15+
16 sites in CA, FL, GA +10
What this study is about
This trial is testing a new treatment called XmAb541 to see if it's safe and well-tolerated. The goal is also to find the best dose for further research, along with evaluating its effect on tumor outcomes.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive XmAb541
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Incidence of adverse events, Incidence of cytokine release syndrome (CRS), Incidence of dose-limiting toxicities (DLTs)
Secondary: Duration of Response, Measurement of Cmax, Measurement of area under curve (AUC), Objective Response Rate
Oncology